| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cencora, Inc.$306.28
-2.09 (-0.68%)
Market Cap
62.41 B
EPS
8.38
P/E Ratio
38.59 $
Value Trade
419.52 M
SEC Financials
Q1 2026Dilution Risk
Revenue
78.36 B
Total Assets
81.65 B
Total Liabilities
81.65 B
Equity
3.40 B
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
2.24 B
Monthly Burn
-
Runway
-
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
2.45 M
52 Week Range
271 - 377.54
% held by Insiders
0.49 %
% held by Institutions
98.01 %
Enterprise Value
68.71 B
Total Shares
194.46 M
Short %
3.15 %
Float Shares
186.29 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cencora, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in COR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
COR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-03-19 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-03-19 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-03-19 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-COR
Aug 5, 2026▼ -0.7%today
Cencora Reports Fiscal 2026 Third Quarter Results
Cencora, Inc. reported a 5.1% increase in revenue for its fiscal 2026 third quarter, totaling $84.8 billion. The diluted earnings per share (EPS) rose to $3.94, compared to $3.52 in the same quarter last year. The financial results indicate a positive trend in the company's performance.
Read more →-COR
Jul 1, 2026Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
Cencora has announced the date and time for its earnings release for the third quarter of fiscal 2026. This announcement is part of the company's regular financial reporting schedule. Further details regarding the earnings report will likely be provided closer to the release date.
Read more →-COR
Jun 17, 2026Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices
Cencora has announced the launch of its next-generation Nucleus® solution, which will be tested through a multi-site pilot across specialty physician practices. This initiative aims to enhance the efficiency and effectiveness of specialty care. Further details on the specific features and benefits of the Nucleus® solution were not disclosed.
Read more →-COR
Jun 15, 2026Cencora Announces Samantha Hammock as Chief Human Resources Officer
Cencora has announced the appointment of Samantha Hammock as the new Chief Human Resources Officer. This leadership change is expected to enhance the company's HR strategies and initiatives. Hammock's experience will be pivotal in driving the company's human resource objectives.
Read more →-COR
May 27, 2026Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
Cencora has announced the appointment of Eva Boratto as the new Executive Vice President and Chief Financial Officer. This strategic move aims to enhance the company's leadership team. Further details about her previous experience or specific goals in this role were not provided in the announcement.
Read more →-COR
May 21, 2026Cencora Announces Updated Fiscal Year 2026 Financial Outlook
Cencora has announced an updated financial outlook for the fiscal year 2026. The details of the financial projections and any significant changes have not been disclosed in the article. Further insights into the company's performance and strategic direction may be expected in future communications.
Read more →-COR
May 6, 2026▼ -17.4%on this news
Cencora Reports Fiscal 2026 Second Quarter Results
Cencora, Inc. reported strong fiscal 2026 second quarter results, with revenue rising 3.8% to $78.4 billion and diluted earnings per share (EPS) increasing to $8.40. The company raised its adjusted diluted EPS guidance for the fiscal year, reflecting confidence in its operational strategy. However, operating expenses surged due to acquisition costs, and interest expenses also increased.
Read more →-COR
May 6, 2026▼ -17.4%on this news
to the Company's Current Report on Form 8-K dated
Cencora, Inc. reported its fiscal 2026 second quarter results, highlighting a 3.8% year-over-year revenue increase to $78.4 billion. The company raised its adjusted diluted earnings per share (EPS) guidance to a range of $17.65 to $17.90, reflecting robust financial performance. Additionally, Cencora is set to repurchase $1 billion in shares by the end of calendar 2026. However, operating expenses surged by 20.9%, and interest expense increased due to financing activities related to a recent acquisition.
Read more →-COR
Mar 23, 2026CENCORA TO EXPAND RETINA CONSULTANTS OF AMERICA THROUGH ACQUISITION OF EYESOUTH PARTNERS' RETINA BUSINESS Cencora reaffirms fiscal 2026 financial guidance CONSHOHOCKEN, PA
Cencora, Inc. has signed an agreement to acquire EyeSouth Partners' retina business for $1.1 billion, aiming to enhance its Retina Consultants of America network. The acquisition is projected to be marginally accretive to Cencora's earnings in the first year post-closing. Although the deal is expected to benefit both organizations in delivering quality patient care, it is still subject to regulatory approvals and customary closing conditions. Cencora has reaffirmed its fiscal 2026 financial guidance, although it does not account for the transaction's closure within that timeframe.
Read more →-COR
Mar 17, 2026CENCORA ANNOUNCES FINANCIAL LEADERSHIP TRANSITION Cencora reaffirms fiscal 2026 financial guidance CONSHOHOCKEN, PA
Cencora, Inc. has announced the retirement of James F. Cleary as its Chief Financial Officer, effective June 30, 2026. Cleary has served in this role since November 2018 and will assist in the transition while remaining until the end of 2026. The company has reaffirmed its adjusted diluted EPS guidance for fiscal 2026, projecting between $17.45 and $17.75. Cencora is a major player in the pharmaceutical solutions sector, emphasizing its commitment to market access and health outcomes.
Read more →-COR
Feb 18, 2026CONFIDENTIAL - Press Release COVETRUS AND MWI ANIMAL HEALTH TO MERGE Combination of companion animal distribution, production animal distribution and technology platforms will make animal healthcare more accessible and a
Cencora and Covetrus have announced a definitive agreement to merge, aimed at creating a comprehensive animal health platform. The merger will enhance accessibility to animal healthcare by combining Covetrus's technology solutions with MWI Animal Health's distribution capabilities. The transaction is valued at $3.5 billion and will see Cencora receive significant equity and cash in the combined entity. However, the deal is subject to customary closing conditions, including regulatory approvals, and Cencora does not anticipate the transaction closing in its fiscal 2026. The merger reflects a strategic move in the evolving animal health sector.
Read more →-COR
Feb 13, 2026CENCORA CLOSES $3.0
Cencora, Inc. has announced the successful completion of a public offering of $3.0 billion in senior notes. The offering includes various notes maturing from 2029 to 2056, with proceeds intended for debt repayment and general corporate purposes. The offering was facilitated by significant underwriters including Citigroup and J.P. Morgan. This move follows Cencora's recent acquisition of OneOncology and aims to enhance its financial positioning.
Read more →-COR
Feb 10, 2026CENCORA PRICES $500 MILLION 3.950% SENIOR NOTES DUE 2029, $500 MILLION 4.250% SENIOR NOTES DUE 2030, $500 MILLION 4.600% SENIOR NOTES DUE 2033, $1.0 BILLION 4.900% SENIOR NOTES DUE 2036 AND $500 MILLION 5.650% SENIOR NOT
Cencora, Inc. has announced the pricing of multiple senior notes totaling $3.5 billion, including notes due between 2029 and 2056. The net proceeds will primarily be used to repay amounts under a recent credit agreement related to the acquisition of OneOncology, with any remaining funds allocated for corporate purposes. The offering follows an effective shelf registration statement filed with the SEC. The successful pricing signals investor confidence in Cencora's financial stability and business strategy.
Read more →-COR
Feb 5, 2026▲ +6.7%on this newsshared move
Cencora Reports Fiscal 2026 First Quarter Results
Cencora, Inc. reported a strong financial performance for the first quarter of fiscal 2026, with a revenue increase of 5.5% year-over-year to $85.9 billion. The company raised its adjusted operating income guidance and reaffirmed its adjusted diluted EPS guidance for the fiscal year. The acquisition of OneOncology is expected to enhance its specialty services in cancer care.
Read more →-COR
Jan 22, 2026Cencora Elects Ellen Cooper to Its Board of Directors
Cencora, Inc. has elected Ellen Cooper as an independent director effective January 20, 2026. Cooper, who is the CEO of Lincoln Financial, brings significant experience in risk management and leadership within regulated industries. Her appointment is expected to support Cencora's long-term growth and strategic initiatives.
Read more →-COR
Jan 22, 2026Press Release
Cencora, Inc. has appointed Ellen Cooper to its Board of Directors, effective January 20, 2026. With a distinguished background in risk management and leadership from Lincoln Financial and Goldman Sachs, her expertise is expected to enhance Cencora's ability to support sustainable growth. The Board aims to leverage Ms. Cooper's strategic insights as the company continues its mission in the healthcare sector.
Read more →-COR
Dec 15, 2025CENCORA ACCELERATES ONEONCOLOGY ACQUISITION, EXTENDING SOLUTIONS OFFERING FOR COMMUNITY ONCOLOGY Company reiterates fiscal 2026 guidance Company raises long-term guidance expectations to reflect OneOncology's expected lo
Cencora, Inc. announced its plan to acquire the majority of OneOncology's equity interests for approximately $3.6 billion, reinforcing its growth strategy focused on enhancing oncology services. This $7.4 billion valuation reflects the significant role OneOncology plays in community oncology. The transaction is expected to close by the end of Cencora's fiscal 2026 second quarter, pending regulatory approvals, and Cencora has reiterated its fiscal 2026 guidance amid this expansion. Notably, the acquisition is expected to bring long-term financial benefits to Cencora.
Read more →-COR
Nov 5, 2025to the Company's form 8-K dated
Cencora, Inc. reported its fiscal 2025 fourth quarter and year-end results, showcasing a revenue increase of 5.9% to $83.7 billion and a 9.3% rise to $321.3 billion for the full year. Despite these revenue gains, the company experienced a negative GAAP EPS of $(1.75) in Q4. Adjusted EPS showed an increase, climbing to $3.84, while the company declared a 9% increase in its quarterly dividend. Cencora also raised its long-term guidance, indicating optimistic growth strategies moving into fiscal 2026.
Read more →-COR
Aug 15, 2025IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LEBANON COUNTY EMPLOYEES' RETIREMENT FUND and TEAMSTERS LOCAL 443 HEALTH SERVICES & INSURANCE PLAN, Plaintiffs, v. STEVEN H. COLLIS, RICHARD W. GOCHNAUER, LON R. GREENBER
Cencora, Inc. has reached a settlement agreement in a stockholder derivative action involving fiduciary duty allegations related to opioid distribution. The settlement aims to fully resolve claims against individual defendants, including significant payments and compliance measures as part of a larger nationwide opioid settlement. While this agreement may bring closure, it raises ongoing concerns about the company's past actions and the implications of the opioid crisis.
Read more →-COR
Aug 6, 2025CENCORA REPORTS FISCAL 2025 THIRD QUARTER RESULTS Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted
Cencora, Inc. reported strong fiscal results for Q3 of 2025, showcasing an 8.7% increase in revenue, reaching $80.7 billion. The company also announced a rise in adjusted diluted earnings per share to $4.00, prompting an upward revision in its EPS guidance for the fiscal year. Despite the positive financial performance, operating expenses saw a notable increase largely driven by the costs associated with recent acquisitions. Additionally, the interest expenses rose significantly due to financing related to these acquisitions.
Read more →-COR
May 7, 2025CENCORA REPORTS FISCAL 2025 SECOND QUARTER RESULTS Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjust
Cencora, Inc. reported substantial growth in its fiscal 2025 second quarter results, with revenues reaching $75.5 billion, marking a 10.3% increase year-over-year. The company's GAAP diluted earnings per share (EPS) rose to $3.68, and the adjusted diluted EPS increased to $4.42. Cencora also updated its guidance for adjusted diluted EPS, raising it to a new range of $15.70 to $15.95 for the fiscal year. Notable factors contributing to this performance include strength in the U.S. Healthcare Solutions segment and successful acquisitions, although interest expenses saw a significant increase due to new debt issuances.
Read more →-COR
Feb 5, 2025CENCORA REPORTS FISCAL 2025 FIRST QUARTER RESULTS Revenue of $81.5 billion for the First Quarter, a 12.8 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.50 and Adjusted Diluted EPS of $3.73 Adjusted
Cencora, Inc. reported a strong fiscal 2025 first quarter with revenues of $81.5 billion, reflecting a 12.8% increase year-over-year. Despite a decrease in GAAP diluted EPS to $2.50 from $2.98, adjusted diluted EPS saw a rise to $3.73. The company also raised its adjusted EPS guidance for the fiscal year, driven in part by the recent acquisition of Retina Consultants of America. Operating income, however, suffered a decline of 14.2% from the previous year due to increased operating expenses.
Read more →-COR
Jan 2, 2025Cencora Completes Acquisition of Retina Consultants of America Acquisition Advances Specialty Leadership Adjusted Diluted EPS Guidance Range Raised to $15.15 to $15.45 for Fiscal 2025 CONSHOHOCKEN, PA
Cencora, Inc. has completed its acquisition of Retina Consultants of America, acquiring approximately 85% interest in the retina management services organization. The deal, valued at $4.4 billion, allows Cencora to strengthen its leadership in specialty healthcare solutions. Following this acquisition, Cencora has raised its adjusted diluted EPS guidance for fiscal year 2025 to a range of $15.15 to $15.45, up from the previous guidance, indicating optimistic financial expectations moving forward.
Read more →-COR
Dec 9, 2024CENCORA CLOSES $1.8
Cencora, Inc. announced the successful closing of its public offering of $1.8 billion in senior notes, consisting of three series due between 2027 and 2035. The company intends to use the proceeds to finance the majority acquisition of Retina Consultants of America and cover related fees. Cencora's decision to issue these notes follows their effective shelf registration with the SEC, which facilitates the offering process. The pharmaceutical solutions organization aims to optimize market access to therapies while enhancing its operational capabilities.
Read more →-COR
Dec 4, 2024Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035
Cencora, Inc. has announced the pricing of senior notes totaling $1.3 billion, which include $500 million due 2027, $600 million due 2029, and $700 million due 2035. The proceeds from the offering will be used to finance the acquisition of the majority of Retina Consultants of America along with related expenses. This offering is registered and is expected to close on December 9, 2024, pending customary closing conditions. Cencora's strong market position is highlighted by its rankings in the Fortune 500.
Read more →-COR
Nov 6, 2024CONFIDENTIAL - Press Release Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America CONSHOHOCKEN, PA
Cencora, Inc. has announced plans to acquire Retina Consultants of America for approximately $4.6 billion in cash. This acquisition is aimed at advancing Cencora's position in the specialty healthcare sector and is expected to enhance patient care through improved operational support. The financial structure of the deal includes components that may result in additional payments based on future performance. The transaction remains subject to regulatory approvals and customary closing conditions.
Read more →-COR
Nov 6, 2024CENCORA REPORTS FISCAL 2024 FOURTH QUARTER AND YEAR END RESULTS Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of
Cencora, Inc. (NYSE COR) reported a revenue of $79.1 billion for Q4 of fiscal 2024, marking a 14.7% year-over-year increase. Despite this growth, the company faced significant challenges with a GAAP diluted EPS of only $0.02, a steep decrease from the previous year's $1.72. Operating expenses rose substantially, primarily due to a goodwill impairment charge and an increase in litigation costs, which led to a notable decline in operating income. The company also announced an 8% increase in its quarterly dividend, reflecting confidence in long-term growth.
Read more →-COR
Jul 31, 2024CENCORA REPORTS FISCAL 2024 THIRD QUARTER RESULTS Revenue of $74.2 billion for the Third Quarter, a 10.9 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.42 and Adjusted Diluted EPS of $3.34 Adjusted
Cencora reported a 10.9% increase in revenue for its fiscal 2024 third quarter, reaching $74.2 billion. The company's diluted EPS also grew to $2.42, while adjusted diluted EPS rose to $3.34. Cencora raised its adjusted diluted EPS guidance for the fiscal year 2024, showcasing strong performance and solid execution of its strategy. However, operating expenses saw a notable increase, and there was a slight decline in the gross profit margin for U.S. Healthcare Solutions.
Read more →-COR
May 22, 2024CENCORA ANNOUNCES COMMON SHARE REPURCHASE FROM WALGREENS BOOTS ALLIANCE AND RAISES FISCAL 2024
Cencora, Inc. announced a share repurchase agreement with Walgreens Boots Alliance totaling approximately $400 million. This decision is part of an opportunistic strategy to manage shares more effectively. Additionally, the company has raised its fiscal year 2024 adjusted diluted earnings per share guidance from $13.30-$13.50 to $13.35-$13.55, reflecting a favorable financial outlook. The repurchase is expected to lower the weighted average diluted share count despite increased interest expenses due to reduced investment balances.
Read more →-COR
May 1, 2024CENCORA REPORTS FISCAL 2024 SECOND QUARTER RESULTS Revenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80 Adjuste
Cencora, Inc. reported its fiscal 2024 second quarter results showing a revenue increase of 7.8% to $68.4 billion. The company raised its adjusted diluted earnings per share (EPS) guidance for the fiscal year, indicating strong financial performance despite a slight decrease in GAAP EPS. Increased operating expenses, influenced by litigation and opioid-related costs, slightly affected operating income margins. The results underscore the company's vital role in healthcare and its strategic focus on customer experience and innovation.
Read more →-COR
Mar 12, 2024CENCORA ANNOUNCES LEADERSHIP SUCCESSION PLAN CEO Steven H. Collis to Transition to Executive Chair; COO Robert P. Mauch to Become President and CEO Both Appointments Effective
Cencora, Inc. has announced a leadership succession plan that will see CEO Steven H. Collis transition to the role of Executive Chair effective October 1, 2024, with COO Robert P. Mauch succeeding him as President and CEO. This strategic change marks a continuation of the company's thoughtful succession planning and aims to build on its momentum as a leading provider of pharmaceutical-centric healthcare solutions. The company also reaffirmed its fiscal year 2024 guidance, reflecting confidence in its ongoing growth and stability. Collis has been a significant figure in Cencora's expansion and success over his 30-year career, while Mauch is expected to carry forward this legacy.
Read more →-COR
Feb 7, 2024CENCORA CLOSES $500
Cencora, Inc. has announced the successful closing of its public offering of $500 million in senior notes with a 5.125% interest rate due in 2034. The funds from this offering will primarily be allocated to redeem the company's existing 3.400% senior notes due in May 2024, with any excess proceeds directed towards general corporate purposes. The offering follows a registered public offering process and utilizes an existing shelf registration statement filed with the SEC. Cencora is noted for its significant role in the pharmaceutical solutions market globally.
Read more →-COR
Feb 5, 2024Final Form CENCORA PRICES $500 MILLION 5.125% SENIOR NOTES DUE 2034 CONSHOHOCKEN, PA
Cencora, Inc. has announced the pricing of $500 million in senior notes at a fixed rate of 5.125%, set to mature in 2034. The offering, which follows an effective shelf registration statement, is expected to conclude on February 7, 2024. The funds raised will primarily be used to redeem outstanding 3.400% senior notes due in May 2024. This strategic financing move aims to enhance the company's financial flexibility for upcoming corporate needs.
Read more →-COR
Jan 31, 2024▲ +5.5%on this newsshared move
CENCORA REPORTS FISCAL 2024 FIRST QUARTER RESULTS Revenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28 Adjusted
Cencora, Inc. reported strong fiscal 2024 first-quarter results, achieving a revenue of $72.3 billion, up 15.0% year-over-year. The diluted earnings per share (EPS) were reported at $2.98, reflecting a 27.9% increase compared to the same quarter last year. The company raised its adjusted diluted EPS guidance for fiscal 2024 to a range of $13.25 to $13.50. Despite these positive results, operating expenses increased significantly by 8.8%, which could impact future profitability.
Read more →-COR
Nov 2, 2023CENCORA REPORTS FISCAL 2023 FOURTH QUARTER AND YEAR END RESULTS Revenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of
Cencora, Inc. reported strong financial results for the fourth quarter and fiscal year 2023, showing a 12.7% increase in revenue to $68.9 billion. Diluted earnings per share also rose, reaching $1.72 in Q4, while the company delivered overall fiscal year revenue growth of 9.9%. However, increased operating expenses and rising interest costs are potential concerns for ongoing profitability. The CEO emphasized the company's commitment to advancing its strategic goals and enhancing value for stakeholders.
Read more →-COR
Aug 30, 2023▲ +5.6%on this news
AmerisourceBergen becomes Cencora, in alignment with the company's growing global footprint and central role in pharmaceutical access and care New name of company reflects unified global presence and collective goal of c
AmerisourceBergen has officially rebranded as Cencora, marking a significant step in the company's evolution within the global pharmaceutical industry. The change aligns with their mission to create healthier futures through improved access to pharmaceutical care. To commemorate the rebranding, Cencora announced a $5 million commitment to support global health initiatives, including a grant to the UNICEF Health Fund. Their focus remains on fostering partnerships and streamlining pharmaceutical distribution to meet the growing complexities of the healthcare sector.
Read more →-COR
Aug 15, 2023▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428
AmerisourceBergen Corporation has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023. This decision expands the Board of Directors from ten to twelve members, emphasizing a strong commitment to enhancing corporate governance. Baumann, previously CEO of Bayer AG, and Tyler, EVP at J.P. Morgan, bring extensive experience that will assist in the company’s ongoing strategic initiatives. Their leadership is expected to bolster AmerisourceBergen's position in the healthcare sector as it transitions to becoming Cencora.
Read more →-COR
Aug 2, 2023▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2023 THIRD QUARTER RESULTS Revenue of $66.9 billion for the Third Quarter, an 11.5 Percent Increase Year-Over-Year
AmerisourceBergen Corporation reported its fiscal 2023 third quarter results, showcasing a significant 11.5% increase in revenue, amounting to $66.9 billion. The company also raised its adjusted diluted earnings per share guidance for the fiscal year to a new range of $11.85 to $11.95. CEO Steven H. Collis highlighted the company's strategic investments and strong performance across business segments. While there was notable revenue growth, the company faced increased operating expenses and challenges with profit margins in certain product categories.
Read more →-COR
Jun 9, 2023▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 TPG and AmerisourceBergen Announce Completion of Acquisition of ONEONCOLOGY CONSHOHOCKEN, PA
AmerisourceBergen Corporation and TPG have finalized their acquisition of OneOncology, with TPG taking a majority interest and AmerisourceBergen a minority stake. This acquisition is expected to bolster OneOncology's resources, allowing for enhanced clinical and operational capabilities that improve patient care. The management team and affiliated practices of OneOncology also retain a minority interest in the company. This collaboration aims to create a more robust platform for improving services in the oncology sector.
Read more →-COR
May 2, 2023▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2023 SECOND QUARTER RESULTS Revenue of $63.5 billion for the Second Quarter, a 9.9 Percent Increase Year-Over-Year
AmerisourceBergen Corporation reported its fiscal 2023 second quarter results, showing a revenue increase of 9.9% year-over-year to $63.5 billion, driven mainly by U.S. Healthcare Solutions. Adjusted diluted earnings per share (EPS) rose by 8.7% to $3.50, prompting an upward revision in full-year guidance to $11.70 to $11.90. Despite these positive financial metrics, challenges such as a decline in GAAP EPS and rising operating expenses were highlighted. The company also experienced a slight drop in revenue from its International Healthcare Solutions segment due to a recent divestiture and unfavorable currency fluctuations.
Read more →-COR
Apr 20, 2023▲ +5.6%on this newsshared move
TPG and AmerisourceBergen TO ACQUIRE LEADING SPECIALTY PRACTICE network ONEONCOLOGY FROM GENERAL atlANTIC Partnership provides nation's largest independent community oncology network with additional resources and experti
TPG and AmerisourceBergen have announced an agreement to acquire OneOncology from General Atlantic, valuing the network at $2.1 billion. This acquisition aims to enhance the operational capabilities of community oncology practices, supporting lower-cost and higher-quality care delivery. The transaction will form a joint venture, with AmerisourceBergen taking a minority stake expected to contribute positively to its earnings. Closing is anticipated by the end of September 2023, pending regulatory approvals.
Read more →-COR
Feb 1, 2023▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2023 FIRST QUARTER RESULTS Revenues of $62.8 billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year
AmerisourceBergen Corporation reported its fiscal Q1 2023 results, revealing revenues of $62.8 billion, up 5.4% year-over-year. The diluted EPS increased to $2.33 from $2.13 in the same quarter previous year, and the company raised its adjusted diluted EPS guidance for the full fiscal year 2023 to a range of $11.50 to $11.75. Despite strong overall performance, revenue from International Healthcare Solutions declined slightly, influenced by unfavorable currency exchange rates. The company's leadership remains optimistic about future growth under its new corporate identity, Cencora.
Read more →-COR
Jan 24, 2023▲ +5.6%on this newsshared move
AmerisourceBergen Announces Intent to Change Name to Cencora Unified corporate identity reflects the organization's global reach, impact, and purpose CONSHOHOCKEN, Pa. (
AmerisourceBergen announced its intention to change its name to Cencora, reflecting its commitment to a unified global identity and future-driven vision. The rebranding aims to enhance its growth strategy and strengthen its position in the healthcare supply chain. The name is inspired by feedback from customers and employees and is expected to create a more inclusive experience internally while focusing on innovation and improved health outcomes. The transition to Cencora is scheduled for the second half of 2023.
Read more →-COR
Jan 3, 2023▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AmerisourceBergen COMPLETES ACQUISITION OF PHARMALEX Acquisition advances role as a partner of choice for biopharmaceutical companies
AmerisourceBergen Corporation has completed the acquisition of PharmaLex Holding GmbH, which bolsters its growth strategy and enhances its offerings in specialty services. This acquisition positions AmerisourceBergen as a leading partner for biopharmaceutical companies by expanding its capabilities in regulatory affairs, consulting, and quality compliance. The move is expected to strengthen its presence in the pharmaceutical development and commercialization landscape.
Read more →-COR
Nov 16, 2022▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN ELECTS REDONDA MILLER, M.D.
PRESS RELEASE AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN ELECTS REDONDA MILLER, M.D., TO ITS BOARD OF DIRECTORS CONSHOHOCKEN, PA, November 16, 2022 - AmerisourceBergen Corporation (NYSE ABC) today announced that its Board of Di
Read more →-COR
Nov 7, 2022▲ +5.6%on this newsshared move
EXPLANATORY NOTE AmerisourceBergen Corporation (the "Company" or "AmerisourceBergen")) is filing this exhibit to reflect changes to the presentation of its financial information as set forth in its Annual Report on Form
AmerisourceBergen Corporation (the "Company" or "AmerisourceBergen")) is filing this exhibit to reflect changes to the presentation of its financial information as set forth in its Annual Report on Form 10-K for the fiscal year ended September 30, 2021 (the "2021 Form 10-K"), as
Read more →-COR
Nov 3, 2022▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2022 FOURTH QUARTER AND YEAR END RESULTS Revenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2022 FOURTH QUARTER AND YEAR END RESULTS Revenue of $61.2 Billion for the Fourth Quarter, a 3.8 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $1.4
Read more →-COR
Sep 27, 2022▲ +5.6%on this newsshared move
Document PRESS RELEASE AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN ELECTS LORENCE H. KIM, M.D.
PRESS RELEASE AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN ELECTS LORENCE H. KIM, M.D., TO ITS BOARD OF DIRECTORS CONSHOHOCKEN, PA, September 27, 2022 - AmerisourceBergen Corporation (NYSE ABC) today announced that its Board of D
Read more →-COR
Sep 12, 2022▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AmerisourceBergen TO EXPAND GLOBAL BIOPHARMA SERVICES PLATFORM WITH ACQUISITION OF PHARMALEX Transaction further advances leadership
AmerisourceBergen TO EXPAND GLOBAL BIOPHARMA SERVICES PLATFORM WITH ACQUISITION OF PHARMALEX Transaction further advances leadership in specialty, with key commercial enablement solutions to support biopharmaceutical partners CONSHOHOCKEN, PA, September 12, 2022 - AmerisourceBe
Read more →-COR
Aug 3, 2022▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2022 THIRD QUARTER RESULTS Revenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2022 THIRD QUARTER RESULTS Revenues of $60.1 billion for the Third Quarter, a 12.5 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $1.92 and Adjusted
Read more →-COR
May 4, 2022▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2022 SECOND QUARTER RESULTS Revenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Ye
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2022 SECOND QUARTER RESULTS Revenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.59 and Adjus
Read more →-COR
Feb 25, 2022▲ +5.6%on this newsshared move
List of states and territories that have agreed to the opioids-related Settlement States and District of Columbia 1. Alaska 25. Missouri 2. Arizona 26. Montana 3. Arkansas 27. Nebraska 4. California 28. Nevada 5. Colorad
List of states and territories that have agreed to the opioids-related Settlement States and District of Columbia 1. Alaska 25. Missouri 2. Arizona 26. Montana 3. Arkansas 27. Nebraska 4. California 28. Nevada 5. Colorado 29. New Hampshire 6. Connecticut 30. New Jersey 7. Delaw
Read more →-COR
Feb 2, 2022▲ +5.6%on this newsshared move
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2022 FIRST QUARTER RESULTS Revenues of $59.6B billion for the First Quarter, a 13.5 Percent Increase Year-Over-Yea
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2022 FIRST QUARTER RESULTS Revenues of $59.6B billion for the First Quarter, a 13.5 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.13 and Adjuste
Read more →-COR
Nov 4, 2021AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2021 FOURTH QUARTER AND YEAR END RESULTS Revenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2021 FOURTH QUARTER AND YEAR END RESULTS Revenue of $58.9 Billion for the Fourth Quarter, a 19.6 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $2.
Read more →-COR
Nov 4, 2021AMERISOURCEBERGEN CORPORATION SUMMARY SEGMENT INFORMATION (in thousands) (unaudited) The following illustrates revised reportable segment revenue for the periods indicated Fiscal Year Ended
AMERISOURCEBERGEN CORPORATION SUMMARY SEGMENT INFORMATION The following illustrates revised reportable segment revenue for the periods indicated Fiscal Year Ended September 30, 2021 Revenue First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year (As Revi
Read more →-COR
Aug 4, 2021AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2021 THIRD QUARTER RESULTS Revenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2021 THIRD QUARTER RESULTS Revenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $1.40 and Adjusted
Read more →-COR
Jul 21, 2021DISTRIBUTORS ANNOUNCE PROPOSED OPIOID SETTLEMENT AGREEMENT CONSHOHOCKEN, PA, DUBLIN, OH and IRVING, TX
DISTRIBUTORS ANNOUNCE PROPOSED OPIOID SETTLEMENT AGREEMENT CONSHOHOCKEN, PA, DUBLIN, OH and IRVING, TX, July 21, 2021 -- AmerisourceBergen (NYSE ABC), Cardinal Health (NYSE CAH) and McKesson (NYSE MCK) announced today that they have negotiated a comprehensive proposed settlement
Read more →-COR
Jun 2, 2021AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN COMPLETES ACQUISITION OF ALLIANCE HEALTHCARE BUSINESSES Acquisition Advances Role as a Key Pillar of Pharmaceutical
PRESS RELEASE AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN COMPLETES ACQUISITION OF ALLIANCE HEALTHCARE BUSINESSES Acquisition Advances Role as a Key Pillar of Pharmaceutical Innovation and Access Adjusted Diluted EPS Guidance Ra
Read more →-COR
May 5, 2021AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2021 SECOND QUARTER RESULTS Revenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Yea
AmerisourceBergen Corporation 1 West First Avenue Conshohocken, PA 19428 AMERISOURCEBERGEN REPORTS FISCAL 2021 SECOND QUARTER RESULTS Revenues of $49.2 billion for the Second Quarter, a 3.7 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.10 and Adjust
Read more →-COR
Mar 30, 2021AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN CLOSES $1,525,000,000 0.737% SENIOR NOTES DUE 2023 AND $1,000,000,000 2.700% SENIOR NOTES DUE 2031
AMERISOURCEBERGEN CLOSES $1,525,000,000 0.737% SENIOR NOTES DUE 2023 AND $1,000,000,000 2.700% SENIOR NOTES DUE 2031 VALLEY FORGE, PA, March 30, 2021 - AmerisourceBergen Corporation (NYSE: ABC) today announced the closing of its public offering of $1,525,000,000 aggregate princi
Read more →-COR
Mar 26, 2021AMERISOURCEBERGEN PRICES $1.525 BILLION 0.737% SENIOR NOTES DUE 2023
AMERISOURCEBERGEN PRICES $1.525 BILLION 0.737% SENIOR NOTES DUE 2023 AND $1.0 BILLION 2.700% SENIOR NOTES DUE 2031 VALLEY FORGE, PA, March 25, 2021 - AmerisourceBergen Corporation (NYSE: ABC) today announced that it priced $1.525 billion aggregate principal amount of its 0.737%
Read more →-COR
Mar 23, 2021Deloitte & Touche LLP 111 S. Wacker Drive Chicago, IL 60606 USA Tel: +1 312 486 1000 Fax: +1 312 247 1000 www.deloitte.com INDEPENDENT AUDITORS' REPORT To the shareholders and the Board of Directors of Walgreens Boots Al
INDEPENDENT AUDITORS' REPORT To the shareholders and the Board of Directors of Walgreens Boots Alliance, Inc.: We have audited the accompanying combined financial statements of certain Pharmaceutical Wholesale and Retail Pharmacy International businesses of Walgreens Boots Alli
Read more →-COR
Feb 4, 2021AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2021 FIRST QUARTER RESULTS Revenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year First Q
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2021 FIRST QUARTER RESULTS Revenues of $52.5 billion for the First Quarter, a 9.7 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $1.81 and Adjusted Diluted
Read more →-COR
Jan 6, 2021AMERISOURCEBERGEN AND WALGREENS BOOTS ALLIANCE ANNOUNCE STRATEGIC TRANSACTION AmerisourceBergen to Acquire Alliance Healthcare Businesses from Walgreens Boots Alliance for $6.5 Billion Allows Walgreens Boots Alliance to
AMERISOURCEBERGEN AND WALGREENS BOOTS ALLIANCE ANNOUNCE STRATEGIC TRANSACTION AmerisourceBergen to Acquire Alliance Healthcare Businesses from Walgreens Boots Alliance for $6.5 Billion Allows Walgreens Boots Alliance to Increase Its Focus on Further Growing Its Core Retail Pha
Read more →-COR
Jan 6, 2021AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN ANNOUNCES UPDATED FISCAL YEAR 2021
EX-99.1 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN ANNOUNCES UPDATED FISCAL YEAR 2021 FINANCIAL OUTLOOK VALLEY FORGE, PA, January 6, 2021 - AmerisourceBergen Corporation (NYSE: ABC) today updated its
Read more →-COR
Nov 5, 2020AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2020 FOURTH QUARTER AND YEAR END RESULTS Revenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Ove
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2020 FOURTH QUARTER AND YEAR END RESULTS Revenue of $49.2 Billion for the Fourth Quarter, a 7.9 Percent Increase Year-Over-Year Fourth Quarter GAAP Diluted EPS of $(23.74) an
Read more →-COR
Aug 5, 2020AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2020 THIRD QUARTER RESULTS Revenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year Third Q
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2020 THIRD QUARTER RESULTS Revenues of $45.4 billion for the Third Quarter, a 0.3 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $1.41 and Adjusted Diluted
Read more →-COR
May 19, 2020AMERISOURCEBERGEN CLOSES $500
AMERISOURCEBERGEN CLOSES $500 MILLION SENIOR NOTE OFFERING VALLEY FORGE, PA, May 19, 2020 - AmerisourceBergen Corporation (NYSE: ABC) today announced the closing of its public offering of $500 million aggregate principal amount of its 2.800% Senior Notes due May 15, 2030 (the "N
Read more →-COR
May 12, 2020AMERISOURCEBERGEN PRICES $500 MILLION 2.800% SENIOR NOTES DUE 2030
AMERISOURCEBERGEN PRICES $500 MILLION 2.800% SENIOR NOTES DUE 2030 VALLEY FORGE, PA, May 12, 2020 - AmerisourceBergen Corporation (NYSE: ABC) today announced that it priced $500 million aggregate principal amount of its 2.800% Senior Notes due May 15, 2030 (the "Notes"), in an u
Read more →-COR
May 7, 2020AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2020 SECOND QUARTER RESULTS Revenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year Seco
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2020 SECOND QUARTER RESULTS Revenues of $47.4 billion for the Second Quarter, a 9.5% Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $4.64 and Adjusted Dil
Read more →-COR
Jan 30, 2020AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2020 FIRST QUARTER RESULTS Revenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year First Q
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2020 FIRST QUARTER RESULTS Revenues of $47.9 Billion for the First Quarter, a 5.4 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $0.90 and Adjusted Diluted
Read more →-COR
Jan 2, 2020AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN ELECTS DENNIS M. NALLY TO ITS BOARD OF DIRECTORS VALLEY FORGE, PA, January 2, 2020 - AmerisourceBergen Corporation (NYSE:ABC) today announced that its Board of Directors elected Dennis M. Nal
Read more →-COR
Nov 7, 2019AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2019 FOURTH QUARTER AND YEAR END RESULTS Revenues of $45.6 Billion for the Fourth Quarter, a 5.4 Percent Increase Year-Ov
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2019 FOURTH QUARTER AND YEAR END RESULTS Revenues of $45.6 Billion for the Fourth Quarter, a 5.4 Percent Increase Year-Over-Year Fourth Quarter GAAP Diluted EPS of $0.63 and
Read more →-COR
Aug 1, 2019AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2019 THIRD QUARTER RESULTS Revenues of $45.2 billion for the Third Quarter, a 4.9 Percent Increase Year-Over-Year Third Q
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2019 THIRD QUARTER RESULTS Revenues of $45.2 billion for the Third Quarter, a 4.9 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $1.43 and Adjusted Diluted
Read more →-COR
May 2, 2019AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2019 SECOND QUARTER RESULTS Revenues of $43.3 billion for the Second Quarter, a 5.6 Percent Increase Year-Over-Year Secon
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2019 SECOND QUARTER RESULTS Revenues of $43.3 billion for the Second Quarter, a 5.6 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $0.13 and Adjusted Dilu
Read more →-COR
Jan 31, 2019AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2019 FIRST QUARTER RESULTS Revenues of $45.4 Billion for the First Quarter, a 12.2 Percent Increase Year-Over-Year First
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2019 FIRST QUARTER RESULTS Revenues of $45.4 Billion for the First Quarter, a 12.2 Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $1.84 and Adjusted Dilute
Read more →-COR
Nov 6, 2018AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2018 FOURTH QUARTER AND YEAR END RESULTS Revenues of $43.3 Billion for the Fourth Quarter, a 10.7 Percent Increase Year-O
AmerisourceBergen Corporation P.O. Box 959 Valley Forge, PA 19482 AMERISOURCEBERGEN REPORTS FISCAL 2018 FOURTH QUARTER AND YEAR END RESULTS Revenues of $43.3 Billion for the Fourth Quarter, a 10.7 Percent Increase Year-Over-Year Fourth Quarter GAAP Diluted EPS of $1.07 and
Read more →Competitive Position
How COR ranks across every disease it competes inCompetitive Position is a premium feature
See how COR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial